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Abstract
Introduction: Bloom syndrome is a rare, autosomal recessive, chromosomal instability disorder caused by
mutations in the BLM gene that increase the risk of developing neoplasias, particularly lymphomas and leukemias,
at an early age.
Case presentation: Case 1 was a 10-year-old Brazilian girl, the third child of a non-consanguineous non-Jewish
family, who was born at 36 weeks of gestation and presented with severe intrauterine growth restriction. She had
Bloom syndrome and was diagnosed with a unilateral Wilms’ tumor at the age of 3.5 years. She responded well to
oncological treatment and has remained disease-free for the last 17 years. Case 2 was a 2-year-old Brazilian girl born
to non-Jewish first-degree cousins. Her gestation was marked by intrauterine growth restriction. She had Bloom
syndrome; a unilateral stage II Wilms’ tumor was diagnosed at the age of 4 years after the evaluation of a sudden
onset abdominal mass. Surgical removal, neoadjuvant chemotherapy and radiotherapy were not sufficient to
control the neoplasia. The tumor recurred after 8 months and she died from clinical complications.
Conclusion: Our study reports the importance of rapid diagnostics and clinical follow-up of these patients.
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Introduction
Bloom syndrome (BS; Online Mendelian Inheritance in
Man database, number 210900) [1] is a rare, autosomal
recessive, chromosomal instability disorder [2] caused by
mutations in the BLM gene, which encodes a product
necessary for the maintenance of genomic stability [3].
The prominent clinical features associated with BS in-
clude severe growth deficiency (pre- and postnatal), sun-
sensitive facial erythema, immunological deficiency and
a remarkably increased risk of developing neoplasias of
various types at a younger age than expected in the gen-
eral population; the neoplasias are the main cause of
death among affected individuals [4,5].
Among the 265 cases of BS reported in the Bloom’s
Syndrome Registry (which includes 222 families), 122
developed some type of neoplasia during their lives; leu-
kemias, lymphomas and carcinomas were common, but
several other cancers have been reported [4,5]. These
patients all present a remarkably increased frequency of
sister chromatid exchange (SCE). The cancer predispos-
ition in patients with BS can be attributed to excessive
chromosomal breakage and homologous recombination
events that lead to spontaneous mutations in the somatic
cells and defective damage response functionality [6].
Wilms’ tumor (WT) is the most common pediatric
solid cancer; it has been estimated to occur in 1:10,000
children below the age of 15 years and was once consid-
ered a rare event among patients with BS [7]. Neverthe-
less, six patients with BS who developed this tumor have
been described previously in the literature [8-11].
Here we report the cases of two new unrelated Brazilian
patients diagnosed with BS who developed WT.
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Case presentation
Case 1
A 10-year-old Brazilian girl, the third child of a non-
consanguineous, non-Jewish family, was born at 36 weeks
of gestation and was marked by severe intrauterine growth
restriction. After resolving the clinical complications of
her extreme low birth weight (BW) of 1500g, she was dis-
charged from the hospital; however, despite presenting
normal cognitive development during the first year of her
life, a remarkable, refractory failure to thrive was noted.
She had recurrent diarrhea and upper and lower respira-
tory tract infections by the age of 1 year and required
prophylactic antibiotics. A WT was diagnosed in her left
kidney after evaluating an abdominal mass at the age of
3.5 years. She underwent surgical removal of the mass and
neoadjuvant chemotherapy (unknown regimen).
The first genetic evaluation occurred at age 10 when a
physical examination revealed features characteristic of
BS, including facial features (elongated face, prominent
nose, prominent ears, malar hypoplasia, and thin upper
vermilion), microcephaly, nose telangiectasias, hypomela-
notic macules in her upper limbs and clinodactyly of her
bilateral fifth fingers. Her anthropometric measurements
were all below the fifth percentile (weight (W) 15.9kg,
height (H) 116cm, and occipital-frontal circumference
(OFC) 46cm; Centers for Disease Control and Prevention
growth charts, National Center for Health Statistics,
USA), and she had developed learning disabilities.
A cytogenetic test was performed to examine the
frequency of SCE using bromodeoxyuridine (BrdU) in
lymphocyte cultures. The results demonstrated an in-
creased frequency of SCE, with an average of 48.5 SCE
per cell (Figure 1A). The G-band karyotype was normal
(46, XX).
She responded well to oncological treatment and has
remained disease-free for the last 17 years. Currently, at
the age of 21, all of her anthropometric measurements
continue to be below the standards for the normal popu-
lation (H: 140cm; W: 26.4kg; and OFC: 47cm).
Case 2
The gestation of a 2-year-old Brazilian girl, who was
born to non-Jewish first-degree cousins, was marked by
intrauterine growth restriction. Vaginal delivery occurred
at term with no complications. The neonate had a low
BW of 2060g, microcephaly (OFC: 30.5cm) and a nor-
mal length (45.5cm); her anthropometric measurements
were all below the fifth percentile. A physical examination
at the age of 2 years revealed a short stature (78cm), low
W (8.1kg), and microcephaly (OFC: 45cm); her anthropo-
metric measurements were all below the fifth percentile.
Features characteristic of BS, including facial features (long,
narrow face; telangiectasic erythema involving her nose,
malar and oral regions; prominent nose; and retrognathia),
café-au-lait macules throughout her body, diffuse hypome-
lanotic macules, and bilateral fifth finger clinodactyly, were
identified. Recurrent upper respiratory tract infections
were common, but she had not experienced any serious in-
fection or required prophylactic antibiotic use.
A stage II unilateral WT was diagnosed at the age of 4
years after the evaluation of a sudden onset abdominal
mass. Surgical removal, neoadjuvant chemotherapy and
radiotherapy were not sufficient to control the neoplasia.
The tumor recurred after 8 months, and the patient died
from clinical complications.
A cytogenetic test was performed to examine the fre-
quency of SCE using BrdU in lymphocyte cultures. The
results demonstrated an increased frequency of SCE,
with an average of 49.5 SCE per cell (Figure 1B). The G-
band karyotype was normal (46, XX).
Discussion
We described two Brazilian patients affected by BS who
each developed a WT at a young age. These two cases,
along with the other six described in the literature
(Table 1) [8-11], increase the estimated frequency of WT
in individuals with BS to at least 3%, a 300-fold increase
in the risk relative to the general pediatric population.
BS is caused by mutations in the BLM gene, whose
product is a 1417-amino acid protein that belongs to the
RecQL helicase group and plays important roles in repli-
cation, recombination and cellular repair. Upon alteration,
BLM loses its function and causes genomic instability and
an increased rate of spontaneous mutations in somatic
cells, primarily by SCE [3]. Cytogenetic analyses of cases 1
and 2 have demonstrated an increase in the frequency of
exchange between sister chromatids, which is pathogno-
monic for BS and confirmed the diagnosis of BS [12]. Un-
equal crossing-over has probably played a major role in
the evolution of various genes and heterochromatin. Hy-
permutability and the hyperrecombinability of somatic
cells leads to an increased chance of homozygous tumor
suppressor genes and/or oncogenes being affected and,
consequently, increases the rate of the development of a
wide variety of neoplasias at an early age [5,8]. In some
cases, retinoblastoma and WT are associated with the
homozygosity of a chromosome segment resulting from a
mitotic crossover. Similarly, the high incidence of cancer
in BS may be caused by a mitotic crossover that leads to
homozygosity or the amplification of oncogenes.
The literature [13] describes that two events lead to
the formation of WT. First, the child inherits one gen-
omic alteration, and a second event occurs in the child
that would be caused easily in BS because of the high
rate of genomic exchanges. Nevertheless, if recombin-
ation in BS occurs as a defect in the repair machinery,
maybe there is another mechanism that may contribute
to the formation of tumors and cancer.
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New technological advances in array-based genomics
revealed the contribution of structural alterations in the
human genome to several different diseases, including
cancer (both solid and hematologic tumors) [14]. In fact,
certain copy number variations (CNVs) potentially com-
promise fundamental processes controlling genomic sta-
bility, including deoxyribonucleic acid (DNA) replication
and the DNA damage response, and have been reported
to be associated with the response to chemotherapy,
which affects the disease prognosis [12]. From a clinical
perspective, CNVs might interfere in the DNA damage
response and create a permissive environment for the
acquisition of additional pathogenic alterations, such as
an individual’s predisposition to cancer [15].
Furthermore, recently, Stephens and colleagues recently
described a novel mechanism of genomic rearrangement
in cancer cells, termed ‘chromothripsis’, that associates spe-
cific CNVs and their contribution to cancer development.
Figure 1 The picture demonstrates the manifold increase of sister chromatid exchange in Case 1 (A) and Case 2 (B). The arrows
exemplify some points of sister chromatid exchange. The lymphocyte cultures were treated with bromodeoxyuridine and staining with
Hoechst 33258-Giemsa.
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Chromothripsis arises through chromosome breakage and
inaccurate reassembly, produces highly complex derivative
chromosomes, and causes oncogene amplification. A disas-
ter of this magnitude could possibly affect both WT alleles
because patients with BS demonstrate susceptibility for
breaks in the genome [16].
In our study, both patients developed WT before 4
years of age; however, despite both patients undergoing
surgical removal of the mass and chemotherapy, the
treatment results were different. The patient described
in case 2 (stage II WT) had a fatal outcome after the re-
currence of the disease, but the patient described in case
1 has remained disease-free after 17 years of follow-up.
All reported cases of WT in patients with BS in the lit-
erature and the two cases described here occurred in pa-
tients aged 8 years or less.
WT has been previously reported in six cases of BS in
the literature [8-11]. The age at which WT was diag-
nosed ranged from 5 months to 8 years. Two of these
cases were diagnosed at early stages (stages I and II) and
had apparently been cured by nephrectomy and chemo-
therapy. Although patients with BS develop cancer at
early ages, the age of onset of WT is the same in litera-
ture reports of patients without previous medical histor-
ies who are under the age of 15 years and in patients
with BS [17].
Thus, the frequency of WT in patients with BS is con-
siderable. Clinicians need to be more aware of this fact,
particularly because the occurrence of WT in patients
with BS was once presumed to be rare. This frequency
summed with the frequencies of other solid tumors in
patients with BS increases the overall frequency of solid
tumors to approximately 12% [5]. Unfortunately, insuffi-
cient attention is given to this group of tumors in pa-
tients with BS.
Beckwith–Wiedemann syndrome is a prototype gen-
etic disease with an increased risk of the development of
early onset solid cancers, mainly WT and hepatoblastoma,
with a total estimated lifelong risk for solid tumors of
7.5% [18]. This increased risk has prompted specialists to
seriously consider solid tumor surveillance because sur-
veillance has been demonstrated to reduce treatment-
related morbidity. Renal ultrasonography is currently the
optimal surveillance modality and is accessible, is non-
invasive and has minor risks [19]. However, this method
may have unfavorable consequences because false positive
results may lead to unnecessary investigations and surgical
procedures.
Although the evidence does not show benefits for
leukemia screening in patients with BS because early
treatment does not improve clinical outcomes, surveil-
lance for solid tumors may have significant advantages
and improve survival [9,10]. In addition, the frequency
of solid tumors in patients with BS is approximately the
same as that for patients with Beckwith–Wiedemann
syndrome, and a screening program has been demon-
strated to be feasible in the latter patients. Thus, we sug-
gest that ultrasound be performed as a regular method
of surveillance for the early detection of solid tumors in
individuals with BS because the early detection of these
tumors may have clinical benefits. The frequency of this
type of screening must be individualized, but the perform-
ance of an ultrasound examination at least every 6 months
is advisable based on the vast experience with Beckwith–
Wiedemann syndrome reported in the literature.
Cytogenetic analyses for SCE are the gold standard
method for the diagnosis of BS. Cytogenetic analysis is
considered a fast and low-cost method to confirm the
diagnosis of BS, and this methodology can be imple-
mented in routine and diagnostic laboratories. Regard-
less, other molecular studies will also be conducted in
living patients.
Conclusions
BS is a rare, autosomal recessive, chromosomal instabil-
ity disorder with remarkably increased risk for develop-
ing neoplasias at a young age. The neoplasias represent
the main cause of death among affected individuals.
Awareness of the high frequency of solid tumors among
patients affected by this disorder must be raised because
these individuals may benefit from individualized screen-
ing for solid tumors, including WT.
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Table 1 Patients affected by Bloom syndrome associated
with Wilms’ tumor
Ashkenazim Consanguinity Age at diagnosis
of WT
References
1 No No 3.5y Our patient
2 No Yes 4y Our patient
3 Yes No 8y [8]
4 No No 5m [8]
5 No No 22m [8]
6 No No 4y [9]
7 Not mentioned Not mentioned 3y [10]
8 No No 3.5y [11]
Abbreviations: m months, WT Wilms’ tumor, y years.
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